Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Theravance Announces FDA Approval of VIBATIV(R) (telavancin) for the Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Theravance Announces FDA Approval of VIBATIV(R) (telavancin) for the Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Theravance Announces FDA Approval of VIBATIV(R) (telavancin) for the Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Submitted by
admin
on June 22, 2013 - 10:25am
Source:
Yahoo/Market Wired
News Tags:
Theravance
Vibativ
hospital-acquired bacterial pneumonia
pneumonia
Headline:
Theravance Announces FDA Approval of VIBATIV(R) (telavancin) for the Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Do Not Allow Advertisers to Use My Personal information
